OR WAIT null SECS
March 02, 2021
Under the terms of the acquisition, OXGENE will become a fully owned subsidiary of WuXi Advanced Therapies, WuXi AppTec’s cell and gene therapy contract testing, development, and manufacturing organization business unit.
The companies intend to design and implement algorithms for the early stages of research for drug discovery and development of drug candidates to treat Alzheimer’s disease.
March 01, 2021
The acquisition strategically expands SPT Labtech’s offering in sample management for life sciences.
The new ultra-sensitive second-generation micro-chip technology is a key enabler in advanced single-cell proteomics workflow.
Through the partnership, Seven Bridges will centralize and manage terabytes of raw and processed scRNASeq data using its cloud-based bioinformatic analysis platform while working to expand Pfizer’s cloud platforms and capabilities.
Currently, the facility manufactures products for oral diabetes treatment and will be expanded to increase capacity for these products.
Through the acquisition, Merck will have access to Pandion’s pipeline of precision immune modulators targeting critical immune control nodes, including its lead candidate, PT101.
February 25, 2021
Under the terms of the partnership, ICQ Consultants will provide consulting and engineering services for the installation, maintenance, qualification, and support of Yokogawa's bioreactor systems and related products in the US.
The company will join the network of approved manufacturers of the lipid excipients.
The site will house development and GMP production capacities for cell and gene therapies, next-generation vaccines, and biopharmaceuticals, to support clients from early clinical trials through commercialization.